Table 1.
Strain | n | Injected with | Injection site | Injection amount | Figure |
---|---|---|---|---|---|
C57BL/6J | 4 (3 M, 1 F) | Retrobeads | OB (dispersed between 2400 and 800 μm ventral) | 900 nl | 2A–C, 3 |
C57BL/6J | 2 M | Retrobeads | OB | 200 nl | 2A–C, 3 |
C57BL/6J | 7 M | AAVretro-GFP | OB | 200 nl | 2D, 4A–G |
C57BL/6J | 2 M | AAVretro-GFP | OT | 500 nl | 4H |
Ai9 | 6 M | AAVretro-Cre | OB | 200 nl | 2E, 5A–G |
Ai9 | 1 M, 1 F | AAVretro-Cre | OT | 500 nl | 5H |
Ai9 | 1 M, 2 sF | AAVretro-Cre | OB (1, 1.5, and 2 mm anterior the rhinal sinus, 1 mm lateral, 1.5 mm ventral) | 200 nl × 3 sites = 600 nl total | 6 |
Unless otherwise noted, OB injections were given at 1.5 mm anterior the rhinal sinus, 1 mm lateral, and 1.5 mm ventral, and OT injections were given at 1.5 mm anterior bregma, 1.2 mm lateral, and 4.8 mm ventral.